隱球菌病治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Cryptococcosis Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月10日 | 出版商:

Global Market Insights Inc. | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在愛滋病毒/愛滋病患者人數不斷增加的推動下，隱球菌病治療市場規模預計 2024 年至 2032 年間複合年成長率將達到 4.7%。

研究人員正在積極開發和改進隱球菌病的治療方法，這種疾病主要影響免疫系統受損的人。這些強化工作旨在加強現有的抗真菌療法並推出新藥，有效控制隱球菌病，特別是在不斷成長的愛滋病毒/愛滋病人口中。這項重點不僅滿足醫療需求，還旨在提高受影響者的健康狀況。據世界衛生組織稱，截至 2023 年底，約有 3,990 萬人感染愛滋病毒。這種不斷擴大的人口突顯了對先進療法的迫切需求，以應對免疫功能低下患者真菌感染的更高風險。

隱球菌病治療產業根據治療、給藥途徑、藥物類型、配銷通路和地區進行細分。

由於各種有效治療方法的廣泛採用，預計到 2032 年，學名藥類型細分市場的市場佔有率將大幅成長。鑑於學名藥相對於品牌學名藥的功效和成本效益已得到證實，因此在治療方案中正變得至關重要。隨著對負擔得起的治療方法的需求不斷增加，學名藥的供應量也在增加，以滿足對可獲得的隱球菌病護理的需求。此外，不斷的進步正在增強這些藥物的有效性並使其應用多樣化。

就配銷通路而言，在線藥房領域的隱球菌病治療市場預計將在 2024 年至 2032 年期間產生可觀的收入。這一激增歸因於人們越來越重視簡化患者獲得抗真菌藥物的過程。線上平台不僅促進處方採購，還簡化了整個藥品採購流程，確保個人可以輕鬆獲得所需的治療。為了支持這一點，線上藥局正在完善其分銷網路，旨在實現更快的交貨時間和更廣泛的治療範圍。

在全球健康計劃的推動下，到 2032 年，歐洲隱球菌病治療產業規模可能會顯著成長。最近的努力重點是提高關鍵抗真菌治療的可及性，例如氟康唑和伊曲康唑，這對於隱球菌病的治療至關重要。這些措施不僅提高了治療的可近性，而且強調了負擔能力。此外，衛生組織和當地機構之間的合作將有望維持這些進步，確保它們適應整個地區不斷變化的患者需求。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Astellas Pharma Inc.
Abbott Laboratories
Bausch Health
Bristol-Myers Squibb Company
Glenmark Pharmaceuticals
Janssen Biotech Inc. (Johnson and Johnson)
Merck and Co., Inc.
Novartis AG
NuCare Pharmaceuticals, Inc.
Pfizer Inc.
Sigmapharm Laboratories LLC
Sun Pharmaceutical Industries Ltd.
Valeant Pharmaceuticals Inc.
Viamet Pharmaceutical Inc.

簡介目錄

Product Code: 10176

Cryptococcosis Therapeutics Market size is expected to record a 4.7% CAGR between 2024 and 2032, driven by the rising HIV/AIDS patient population.

Researchers are actively developing and refining treatments for cryptococcosis, a condition that predominantly affects those with compromised immune systems. These intensified efforts aim to enhance existing antifungal therapies and introduce new drugs, effectively managing cryptococcosis, especially in the growing HIV/AIDS demographic. This focus not only addresses the medical needs but also aims to uplift the health outcomes of those affected. According to WHO, as of the end of 2023, approximately 39.9 million individuals were living with HIV. This expanding demographic underscores the pressing demand for advanced therapeutics to counteract the heightened risk of fungal infections in immunocompromised patients.

The cryptococcosis therapeutics industry is segmented based on treatment, route of administration, drug type, distribution channel, and region.

The market share from the generics drug type segment is expected to grow substantially through 2032, due to expanding adoption for a diverse range of effective therapeutics. Generics are becoming pivotal in treatment protocols, given their proven efficacy and cost-effectiveness over brand-name counterparts. With a rising need for affordable treatments, the availability of generics is rising to cater to the demand for accessible cryptococcosis care. Furthermore, ongoing advancements are amplifying the effectiveness of these drugs and diversifying their applications.

In terms of distribution channel, the cryptococcosis therapeutics market from the online pharmacies segment is slated to generate notable revenue during 2024-2032. This surge is attributed to the growing emphasis on simplifying access to antifungal medications for patients. Online platforms are not just facilitating prescription acquisitions but are also streamlining the entire medication procurement process, ensuring individuals can conveniently access their required treatments. To bolster this, online pharmacies are refining their distribution networks, aiming for quicker delivery times and a broader therapeutic range.

Europe cryptococcosis therapeutics industry size is likely to record a notable growth rate through 2032 driven by global health initiatives. Recent endeavors have focused on enhancing access to key antifungal treatments, such as fluconazole and itraconazole, pivotal for cryptococcosis management. These initiatives not only boost treatment accessibility but also emphasize affordability. Furthermore, collaborations between health organizations and local agencies will promise to sustain these advancements, ensuring they adapt to the evolving patient needs across the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of cryptococcal infections
  - 3.2.1.2 Advancements in diagnostic technologies
  - 3.2.1.3 Development of novel antifungal drugs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High treatment costs
  - 3.2.2.2 Antifungal resistance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Flucytosine
5.3 Amphotericin B
5.4 Fluconazole
5.5 Other treatments

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Intravenous
6.4 Inhalation

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Branded
7.3 Generic

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa